×

Merck-Cubist deal about 'superbugs'

9:09 AM ET Mon, 8 Dec 2014

CNBC's David Faber and Jim Cramer discuss Merck's acquisition of Cubist Pharmaceuticals for $8.4 billion in cash plus $1.1 billion in debt.